Shares of diagnostics company, Natera, Inc. (NTRA) are rising more than 15% Thursday morning at $49.03.
The company today said it received confirmation about Medicare extending coverage for Natera's Signatera test for breast cancer.
The coverage will include serial monitoring in all subtypes, including hormone receptor-positive, HER2-positive, and triple negative breast cancers, the company said.
NTRA has traded in the range of $26.10-$71.00 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.